Clinical trials: Dementia, Moderate
Alzheimer's Disease
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.
- Trial name
- NCT01825330
- Testing
- TMS and cognitive stimulation
- Where
- 10 sites in United States, Israel
- Volunteers
- 131 people
- Sponsor
- Neuronix Ltd
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
Alzheimer Disease, Mild to Moderate
TMS Stimulation and Cognitive Training in Alzheimer Patients
The aim of this study is to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of mild to moderate Alzheimer's…
- Trial name
- NCT01168245
- Testing
- NICE-System
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT01527916
- Testing
- donepezil, ABT-126
- Where
- 33 sites in United States, Poland and 4 more
- Volunteers
- 438 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Alzheimer's Disease
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01908010
- Testing
- ABT-354
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie